RT Journal Article
SR Electronic
T1 ROR1 is a novel putative druggable target for diffuse glioma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.03.21267166
DO 10.1101/2021.12.03.21267166
A1 John, Miya
A1 Rao, Padmashree
A1 Noor, Humaira
A1 Ford, Caroline
YR 2021
UL http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267166.abstract
AB The cell surface receptor ROR1 is a therapeutic target of growing interest in oncology; however, its role in glioma has not been established thus far. This study analyzed associations between ROR1 mRNA expression and clinical outcomes, and histological and molecular subtypes in four independent glioma (grades II-IV) transcriptomic datasets (The Cancer Genome Atlas-GBMLGG, Chinese Glioma Genome Atlas, Repository for Molecular Brain Neoplasia, and GSE16011), encompassing a total of 2,388 cases. The data strongly suggests that ROR1 may be associated with poorer outcomes and more aggressive disease. Taken together, ROR1 should be further examined as a novel putative druggable target for glioma, a cancer that currently has very limited therapeutic options.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported in part by a Major Pilot Grant to CF from the Translational Cancer Research Group, an initiative of the Cancer Institute New South Wales, and an Early Career Research Grant to MJ from Tour de Cure.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available human data, which can be obtained from: http://gliovis.bioinfo.cnio.es/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.